Bio-Techne Corporation (TECH)

Market Cap	8.25B
Revenue (ttm)	1.21B
Net Income (ttm)	131.64M
Shares Out	156.77M
EPS (ttm)	0.83
PE Ratio	63.40
Forward PE	26.30
Dividend	$0.32 (0.61%)
Ex-Dividend Date	May 19, 2025

Volume	1,592,127
Open	53.37
Previous Close	54.14
Day's Range	52.29 - 53.68
52-Week Range	46.01 - 83.62
Beta	1.38
Analysts	Buy
Price Target	70.00 (+33.03%)
Earnings Date	Aug 6, 2025

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In 2024, Bio-Techne's revenue was $1.16 billion, an increase of 1.97% compared to the previous year's $1.14 billion. Earnings were $168.07 million, a decrease of -41.07%.

Analyst Summary

According to 12 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $70.0, which is an increase of 33.03% from the latest price.

Price Target

$70.0

(33.03% upside)

Analyst Consensus: Buy